ArticleJournal of biological engineering2026
Elucidating the metabolic landscape of Bacillus velezensis WY-65 in basic and cocktail nutrient media: a biocontrol approach against peanut web blotch.
Article in Journal of biological engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn this study, the cocktail medium significantly enhanced antifungal metabolite production, thereby improving the suppression of peanut web blotch caused by Peyronellaea arachidicola.
resultsA novel antagonistic bacterial strain was isolated from cultivated peanut soil and identified as Bacillus velezensis WY-65. Additionally, the metabolomic profile of strain WY-65 was investigated under two fermentation conditions: basic fermentation medium (BFM) and cocktail fermentation medium (CFM). In vitro assays revealed that the cell-free supernatant (CFS) from WY-65 cultured in CFM inhibited P. arachidicola by 87.68%, whereas the CFS from BFM inhibited P. arachidicola by 61.42%. Greenhouse trials targeting peanut web blotch demonstrated that CFM achieved a disease control efficiency of 92%, whereas BFM exhibited a control efficiency of 86%. Treatment with CFM reduced the disease incidence to 8.71%, and BFM treatment resulted in a disease incidence of 15%. In contrast, the control group presented a disease incidence of 95%. CFS significantly impacted the efflux pump and caused ROS in P. arachidicola. Using untargeted LC‒MS/UHPLC-based metabolomics, we identified distinct metabolic signatures influenced by medium composition, revealing an enrichment of bioactive secondary metabolites, including 3-indoleacrylic acid and L-tryptophan, in CFM. KEGG differential abundance (DA) analysis revealed that strain WY-65 cultured in CFM underwent broad metabolic reprogramming, with significant enrichment in amino acid biosynthesis and the phenylalanine, tyrosine, and tryptophan synthesis pathways. Pathway topology analysis further revealed that glycine, serine, and threonine metabolism and phenylalanine, tyrosine, and tryptophan synthesis pathways had the greatest impact and significance, highlighting their central roles in stress adaptation and antimicrobial precursor biosynthesis. In vitro confirmatory tests with synthetic chemicals confirmed the bioactivity of these compounds. At 200 μL, both 3-indoleacrylic acid and L-tryptophan exhibited peak antifungal activity (91% and 89%, respectively), whereas their activities at 150 μL (87% vs. 75%) and 300 μL (89% vs. 80%) were comparatively lower.
conclusionOur findings provide insight into medium-induced metabolomic modulation in strain WY-65 and highlight its potential as a robust biocontrol agent for sustainable peanut web blot disease management. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.